劲方医药-B(02595)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

02595 劲方医药-B

交易中 08-14 10:11:32

30.740

-0.680

-2.16%

最高32.000	最低30.400	成交量15.82万
今开32.000	昨收31.420	日振幅5.09%
总市值118.04亿	流通市值108.20亿	总股本3.84亿
成交额495.88万	换手率0.04%	流通股本3.52亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"02595","market":"HK","secType":"STK","nameCN":"劲方医药-B","latestPrice":30.74,"timestamp":1786673486144,"preClose":31.42,"halted":0,"volume":158200,"delay":0,"changeRate":-0.021642266072565346,"floatShares":352000000,"shares":384000000,"eps":-6.07,"marketStatus":"交易中","change":-0.68,"latestTime":"08-14 10:11:32","open":32,"high":32,"low":30.4,"amount":4958784,"amplitude":0.050923,"askPrice":30.78,"askSize":1600,"bidPrice":30.68,"bidSize":600,"shortable":3,"etf":0,"ttmEps":-5.174,"tradingStatus":2,"nextMarketStatus":{"tag":"午间休市","tradingStatus":4,"beginTime":1786680000000},"marketStatusCode":2,"adr":0,"listingDate":1758211200000,"exchange":"SEHK","adjPreClose":31.42,"openAndCloseTimeList":[[1786671000000,1786680000000],[1786683600000,1786694400000]],"volumeRatio":0.775001,"lotSize":200,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/02595","defaultTab":"news","newsList":[{"id":"1136722045","title":"财报前瞻｜劲方医药-B本季度营收预计待披露，机构观点偏谨慎","url":"https://stock-news.laohu8.com/highlight/detail?id=1136722045","media":"财报Agent","labels":["earningPreview"],"top":1,"itemType":null,"share":"https://www.laohunote.com/m/news/1136722045?lang=zh_cn&edition=full","pubTime":"2026-08-14 08:46","pubTimestamp":1786668364,"startTime":"0","endTime":"0","summary":"劲方医药-B将于2026年08月21日发布最新季度财报，市场关注临床推进与费用控制对单季亏损的影响及毛利率趋势。由于缺乏覆盖机构在公开渠道披露的本季度一致预期与公司指引，当前市场对劲方医药-B本季度的营收、毛利率、净利润或净利率、调整后每股收益的量化预测暂未形成共识。对劲方医药-B而言，若本季度维持积极推进关键研究节点，短期利润表仍将承压，但也可能带来合作里程碑或授权金的阶段性确认，形成对收入与毛利率的短期支撑。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"财报前瞻｜劲方医药-B本季度营收预计待披露，机构观点偏谨慎","news_tag":"earningPreview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02595"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658072876","title":"港股异动 | 劲方医药-B(02595.HK)涨近4% GFH375在国内进入单药治疗非小细胞肺癌注册性III期临床研究","url":"https://stock-news.laohu8.com/highlight/detail?id=2658072876","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2658072876?lang=zh_cn&edition=full","pubTime":"2026-08-10 13:44","pubTimestamp":1786340676,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["09939","BK1515","02595","BK1574","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658605432","title":"劲方医药-B(02595.HK)：全球首个口服KRAS G12D抑制剂治疗非小细胞肺癌III期研究启动，GFH375第二项注册性临床研究完成首例患者入组","url":"https://stock-news.laohu8.com/highlight/detail?id=2658605432","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2658605432?lang=zh_cn&edition=full","pubTime":"2026-08-10 08:13","pubTimestamp":1786320788,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["09939","BK1515","02595","BK1574","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1109928638","title":"劲方医药-B（02595.HK）：GFH375进入中国KRAS G12D突变非小细胞肺癌注册性III期临床研究","url":"https://stock-news.laohu8.com/highlight/detail?id=1109928638","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1109928638?lang=zh_cn&edition=full","pubTime":"2026-08-10 08:02","pubTimestamp":1786320128,"startTime":"0","endTime":"0","summary":"劲方医药-B（GENFLEET-B，股票代码：02595）宣布，其核心在研药物GFH375正式迈入中国注册性III期临床研究阶段，针对的适应症为KRAS G12D突变型非小细胞肺癌（NSCLC）。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02595","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657572325","title":"劲方医药-B(02595.HK)拟8月21日举行董事会会议以审批中期业绩","url":"https://stock-news.laohu8.com/highlight/detail?id=2657572325","media":"中金财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2657572325?lang=zh_cn&edition=full","pubTime":"2026-08-06 06:57","pubTimestamp":1785970621,"startTime":"0","endTime":"0","summary":"格隆汇8月6日丨劲方医药-B(02595.HK)宣布，公司将于2026年8月21日(星期五)举行董事会会议，旨在(其中包括)审议及批准公司及其附属公司截至2026年6月30日止六个月的中期业绩及其发布，以及考虑派发中期股息(如有)。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushizhibo/20260806/32327143.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["BK1515","02595","09939","159938","BK1574","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1188216906","title":"劲方医药科技（上海）股份有限公司（02595）拟于2026年8月21日审议中期业绩","url":"https://stock-news.laohu8.com/highlight/detail?id=1188216906","media":"公告速递","labels":["dataReport","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1188216906?lang=zh_cn&edition=full","pubTime":"2026-08-06 06:05","pubTimestamp":1785967540,"startTime":"0","endTime":"0","summary":"劲方医药科技（上海）股份有限公司（02595）6日公告，公司董事会将于2026年8月21日（星期五）召开会议，审议并批准公司及其附属公司截至2026年6月30日止六个月的中期业绩及其发布事宜，并将同时考虑是否派发中期股息（如有）。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02595"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1178217906","title":"劲方医药-B 7月股份变动月报：H股新发行13,600,000股","url":"https://stock-news.laohu8.com/highlight/detail?id=1178217906","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1178217906?lang=zh_cn&edition=full","pubTime":"2026-08-05 17:22","pubTimestamp":1785921732,"startTime":"0","endTime":"0","summary":"劲方医药科技（上海）股份有限公司于2026年8月5日发布截至2026年7月31日的证券变动月报表，披露了报告期内股本变动及相关信息。公司普通股H股在香港联交所上市，面值为每股人民币0.1元。截至本月末，已发股本总额为人民币38,396,663元。根据月报，本月新增H股主要来自于2026年7月17日完成的一次配售发行，共计13,600,000股，发行价格为每股港币34.69元。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02595"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1138812924","title":"异动解读｜劲方医药-B盘中上涨5.45%，报28.24港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1138812924","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1138812924?lang=zh_cn&edition=full","pubTime":"2026-07-31 10:32","pubTimestamp":1785465135,"startTime":"0","endTime":"0","summary":"7月31日，劲方医药-B盘中上涨5.45%，报28.24港元/股，成交额2757.3万港元。劲方医药-B所在的生物科技行业中，个股中，信达生物跌0.06%，康方生物涨2.09%，百济神州跌0.61%，三生制药跌2.3%，科伦博泰生物涨1.7%。劲方医药科技（上海）有限公司是一家专注于创新药物研发的中国公司，主要为肿瘤、自身免疫性疾病和炎症性疾病提供新型治疗方案，研发平台涵盖靶点发现、分子发现与评估、转化科学和临床开发等环节。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02595"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1144032358","title":"异动解读｜劲方医药-B盘中下跌5.41%，竞品RAS抑制剂NDA获FDA受理持续承压","url":"https://stock-news.laohu8.com/highlight/detail?id=1144032358","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1144032358?lang=zh_cn&edition=full","pubTime":"2026-07-30 11:24","pubTimestamp":1785381871,"startTime":"0","endTime":"0","summary":"7月30日，劲方医药-B盘中下跌5.41%，报26.32港元，成交额2148.64万港元，连续第三个交易日走低。消息面上，竞争对手Revolution Medicines的口服RAS抑制剂daraxonrasib的NDA已获FDA受理，该申请基于其关键III期RASolute 302研究数据。劲方医药核心产品GFH375同为KRAS G12D抑制剂，目前正开展针对二线及以上胰腺癌的III期注册性临床研究，竞品率先推进上市审评对公司同类最佳定位构成持续压力。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"劲方医药-B盘中下跌5.41%，竞品RAS抑制剂NDA获FDA受理持续承压","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02595"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1119350283","title":"异动解读｜劲方医药-B盘中下跌5.49%，竞品RAS抑制剂NDA获FDA受理持续承压","url":"https://stock-news.laohu8.com/highlight/detail?id=1119350283","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1119350283?lang=zh_cn&edition=full","pubTime":"2026-07-29 09:59","pubTimestamp":1785290385,"startTime":"0","endTime":"0","summary":"7月29日，劲方医药-B盘中下跌5.49%，报27.16港元，成交额1647.53万港元，延续前一交易日跌势。消息面上，竞争对手Revolution Medicines的口服RAS抑制剂daraxonrasib的NDA已获FDA受理，该申请基于其关键III期RASolute 302研究数据。劲方医药核心产品GFH375同为KRAS G12D抑制剂，目前正开展针对二线及以上胰腺癌的III期注册性临床研究，竞品率先推进上市审评对公司管线的同类最佳定位构成持续压力。此外，机构Wellington Management近期亦有小幅减持动作，市场情绪偏弱。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"劲方医药-B盘中下跌5.49%，竞品RAS抑制剂NDA获FDA受理持续承压","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02595"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1169248622","title":"异动解读｜劲方医药-B盘中下跌5.12%，竞品RAS抑制剂NDA获FDA受理引发竞争担忧","url":"https://stock-news.laohu8.com/highlight/detail?id=1169248622","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1169248622?lang=zh_cn&edition=full","pubTime":"2026-07-28 10:10","pubTimestamp":1785204616,"startTime":"0","endTime":"0","summary":"7月28日，劲方医药-B盘中下跌5.12%，报31.48港元，成交额751.94万港元。消息面上，竞争对手Revolution Medicines的口服RAS抑制剂daraxonrasib的NDA已获FDA受理，基于其关键III期研究数据。劲方医药核心产品GFH375同为KRAS G12D抑制剂，竞品率先推进上市审评对公司管线的同类最佳定位构成压力。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"劲方医药-B盘中下跌5.12%，竞品RAS抑制剂NDA获FDA受理引发竞争担忧","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02595"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653744752","title":"Wellington Management Group LLP减持劲方医药-B(02595)8400股 每股作价约34.71港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2653744752","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2653744752?lang=zh_cn&edition=full","pubTime":"2026-07-22 19:18","pubTimestamp":1784719136,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，香港联交所最新数据显示，7月20日，Wellington Management Group LLP减持劲方医药-B(02595)8400股，每股作价34.7105港元，总金额约为29.16万港元。减持后最新持股数目约为2444.11万股，最新持股比例为6.95%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1471034.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02595","BK1574","BK1161","159938","09939","EWH","BK1515"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1178119709","title":"异动解读｜劲方医药-B盘中上涨5.76%，配售落地后股价技术性修复","url":"https://stock-news.laohu8.com/highlight/detail?id=1178119709","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1178119709?lang=zh_cn&edition=full","pubTime":"2026-07-21 13:28","pubTimestamp":1784611682,"startTime":"0","endTime":"0","summary":"7月21日，劲方医药-B盘中上涨5.76%，报38.2港元/股，成交额2611.66万港元。消息面上，公司于7月17日完成1360万股新H股配售，每股配售价34.69港元，净筹约4.67亿港元，用于推进核心产品RAS抑制剂GFH276、GFS202A及GFS784等创新管线研发。配售当日股价下跌8.56%，今日股价在配售价上方展开修复。此外，公司多项研究数据已获WCLC、ESMO口头报告或突破性研究摘要入选，核心管线GFH375此前已获两项突破性疗法认定。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02595"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1101958803","title":"劲方医药-B配发及发行1360万股H股，涉资约4.72亿港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1101958803","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1101958803?lang=zh_cn&edition=full","pubTime":"2026-07-17 19:51","pubTimestamp":1784289114,"startTime":"0","endTime":"0","summary":"劲方医药科技（上海）股份有限公司（劲方医药-B，股票代码：02595）于2026年7月17日发布公告，宣布根据于2026年7月14日订立的配售协议，并依据一般授权，配发及发行13,600,000股新H股。该等股份占发行前已发行股本约4.02%，每股发行价为34.69港元，总发行金额约为4.72亿港元。\n本次股份发行完成后，公司已发行股本由338,029,020股增至351,629,020股，公司库藏股维持不变。公司在公告中确认，相关发行已获得董事会正式授权，并符合香港联合交易所有限公司的上市规则及其他相关法规。\n本公告由联席公司秘书张巍签署。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"劲方医药-B配发及发行1360万股H股，涉资约4.72亿港元","news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02595"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2652205288","title":"Wellington Management Group LLP增持劲方医药(02595)139.74万股 每股作价34.69港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2652205288","media":"智通财经网","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2652205288?lang=zh_cn&edition=full","pubTime":"2026-07-17 19:41","pubTimestamp":1784288466,"startTime":"0","endTime":"0","summary":"7月15日，Wellington Management Group LLP增持劲方医药(02595)139.74万股，每股作价34.69港元，总金额约为4847.58万港元。","market":"hk","thumbnail":"https://img.zhitongcaijing.com/image/20260717/20260717194140_39306.png?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250","type":0,"news_type":0,"thumbnails":["https://img.zhitongcaijing.com/image/20260717/20260717194140_39306.png?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1469199.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["BK1515","EWH","BK1161","BK1574","02595","159938","09939"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2652840045","title":"劲方医药-B(02595)完成发行1360万股配售股份","url":"https://stock-news.laohu8.com/highlight/detail?id=2652840045","media":"智通财经网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2652840045?lang=zh_cn&edition=full","pubTime":"2026-07-17 19:38","pubTimestamp":1784288297,"startTime":"0","endTime":"0","summary":"智通财经APP讯，劲方医药-B 发布公告，配售协议所载的全部条件已获达成，且交割已根据配售协议的条款于2026年7月17日进行。配售代理已根据配售协议的条款及条件按配售价每股配售股份34.69港元成功向不少于六名承配人配售合共1360万股配售股份，于本公告日期，约占经配发及发行配售股份扩大后的H股的3.87%及已发行股份总数的3.54%。配售的所得款项总额为4.718亿港元，而配售的所得款项净额为约4.669亿港元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1469195.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["09939","BK1574","BK1515","02595","159938","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1174244833","title":"劲方医药-B(02595)完成3.54%新H股配售  净筹4.67亿港元并修订公司章程","url":"https://stock-news.laohu8.com/highlight/detail?id=1174244833","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1174244833?lang=zh_cn&edition=full","pubTime":"2026-07-17 19:35","pubTimestamp":1784288127,"startTime":"0","endTime":"0","summary":"2026年7月17日，劲方医药科技（上海）股份有限公司公告称，公司已完成根据董事会一般授权进行的新H股配售，并同步修订公司章程。本次配售由独家全球协调人负责承销，配售协议的全部条件已于2026年7月17日达成并完成交割。配售价格为每股34.69港元，向不少于六名承配人发行合计13,600,000股H股，占配售完成后扩大后已发行H股的约3.87%，占已发行股份总数的约3.54%。其中，未上市股份保持32,337,610股，占总股本的8.42%；H股增至351,629,020股，占总股本的91.58%。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02595"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1155736708","title":"异动解读｜劲方医药-B盘中下跌8.2%，报35.84港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1155736708","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1155736708?lang=zh_cn&edition=full","pubTime":"2026-07-17 11:10","pubTimestamp":1784257818,"startTime":"0","endTime":"0","summary":"7月17日，劲方医药-B盘中下跌8.2%，报35.84港元/股，成交额3741.79万港元。劲方医药-B所在的生物科技行业整体承压，个股中，康方生物跌11.64%，三生制药跌11.5%，信达生物跌5.57%，科伦博泰生物跌5.45%，百济神州跌2.62%。值得关注的是，公司于7月15日公告拟折价约9.71%配售1360万股新H股，净筹约4.67亿港元用于推进RAS抑制剂等核心管线研发，此前两个交易日股价累计大幅上涨后，今日随板块整体回落。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02595"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651380424","title":"港股异动 | 劲方医药-B(02595.HK)早盘涨超7% 拟配股净筹约4.7亿港元 用于推进核心产品RAS抑制剂等","url":"https://stock-news.laohu8.com/highlight/detail?id=2651380424","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2651380424?lang=zh_cn&edition=full","pubTime":"2026-07-15 09:46","pubTimestamp":1784079989,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["09939","BK1161","02595","BK1515","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1131195780","title":"港股直击｜医药股及医药外包股造好，昭衍新药升6%，劲方医药、康宁杰瑞制药升逾5%","url":"https://stock-news.laohu8.com/highlight/detail?id=1131195780","media":"老虎资讯综合","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1131195780?lang=zh_cn&edition=full","pubTime":"2026-07-15 09:38","pubTimestamp":1784079537,"startTime":"0","endTime":"0","summary":"医药股及医药外包股造好，劲方医药升逾 5%，拟折价约9.71%配售1360万股配售股份，净筹约4.67亿港元；康宁杰瑞制药升 5%，康方生物升 4%，昭衍新药升 6%。","market":"hk","thumbnail":"https://static.tigerbbs.com/5caed408891c5ae9176e1a31289a0785","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/5caed408891c5ae9176e1a31289a0785"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06127","02595"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.genfleet.com","stockEarnings":[{"period":"1week","weight":0.1174},{"period":"1month","weight":-0.1822},{"period":"3month","weight":-0.1204},{"period":"6month","weight":0.0397},{"period":"1year","weight":0.541},{"period":"ytd","weight":0.3213}],"compareEarnings":[{"period":"1week","weight":-0.0052},{"period":"1month","weight":0.0434},{"period":"3month","weight":-0.0218},{"period":"6month","weight":-0.0441},{"period":"1year","weight":-0.0085},{"period":"ytd","weight":-0.0091}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"劲方医药科技（上海）有限公司是一家专注于创新药物研发的中国公司。该公司为肿瘤、自身免疫性疾病和炎症性疾病提供有效的新型治疗方案。该公司的研发平台涵盖靶点发现、分子发现与评估、转化科学和临床开发，以及制剂研究、工艺开发和质量分析等关键化学生产和控制环节。该公司主要致力于新分子类型和新药物模式的开发，分子工艺路线和质量标准的研究，以及差异化临床开发策略和路径的探索。该公司主要在中国国内和海外市场开展业务。","exchange":"SEHK","name":"劲方医药-B","nameEN":"GENFLEET-B"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"劲方医药-B(02595)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供劲方医药-B(02595)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"劲方医药-B,02595,劲方医药-B股票,劲方医药-B股票老虎,劲方医药-B股票老虎国际,劲方医药-B行情,劲方医药-B股票行情,劲方医药-B股价,劲方医药-B股市,劲方医药-B股票价格,劲方医药-B股票交易,劲方医药-B股票购买,劲方医药-B股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"劲方医药-B(02595)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供劲方医药-B(02595)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}